Latest Breaking News On - Biomarin roctavian - Page 1 : vimarsana.com

Pfizer s first gene therapy gets approval for clotting disorder

Pfizer Inc. won U.S. approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business. The treatment, called Beqvez, gained clearance for .

Ellis neufeldBiomarin roctavianPfizer incJude children research hospital in memphisMarin pharmaceuticalJude childrenResearch hospitalWall street

Pfizer s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer s First Gene Therapy Gets Approval for Clotting Disorder
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Ellis neufeldBiomarin roctavianBloomberg pfizer incJude children research hospital in memphisMarin pharmaceuticalJude childrenResearch hospitalWall street

BioMarin shares long-term results for haemophilia A gene therapy Roctavian

BioMarin shares long-term results for haemophilia A gene therapy Roctavian
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Biomarin roctavianHank fuchsEuropean commissionEuropean association for haemophiliaDrug administrationDisorders congressMarin pharmaceuticalEuropean associationAllied disorders congress

Uptake of new hemophilia gene therapies slow as field assesses options

By Deena Beasley (Reuters) - High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene.

San diegoUnited statesMichael rechtCaroline humerBob lojewskiBiomarin roctavianMargaret ragniDeena beasleyNational bleeding disorders foundationAmerican society of hematologyUniversity of pittsburghAmerican societyReporting by deena beasleyBill berkrot

Uptake of new hemophilia gene therapies slow as field assesses options

High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene therapies for hemophilia, experts said this week during the American Society.

San diegoUnited statesMichael rechtBob lojewskiMargaret ragniCaroline humerBiomarin roctavianAmerican society of hematologyNational bleeding disorders foundationUniversity of pittsburghAmerican societyReporting by deena beasley editingBill berkrot